



ASX/ Media Release
3 May 2017

OncoSil Appoints Dr. Chris Roberts AO as Chairman

Sydney, Australia, 3 May 2017: OncoSil Medical Limited (ASX: OSL) (**OncoSil Medical** or the **Company**), a medical device company focused on localized treatments for patients with pancreatic and liver cancer, is pleased to announce the appointment of Dr. Chris Roberts AO as Non-Executive Chairman of the Board following his involvement as a Non-Executive Director since January 2016. The appointment will take effect on May 8th 2017.

Dr. Roberts has over 40 years' experience in the medical innovations space, having forged a long and successful career as both a director and senior executive of ASX listed companies, research institutions, and government entities. In January 2017 Dr Roberts was appointed an Officer in the Order of Australia for his service to science and the development and commercialisation of medical biotechnology.

He was Chief Executive Officer/President of Cochlear Limited (ASX:COH) from February 2004 to August 2015. Cochlear is the global leader in implantable devices for the hearing impaired. Dr Roberts was also previously Chairman of Sirtex Medical Ltd (ASX: SRX), from March 2000 – December 2002, and was Executive Vice-President of global sleep disorder treatment company ResMed Inc (NYSE: RMD, ASX: RMD) from 1992-2004. He is currently a Non-Executive Director of ResMed Inc.

Dr. Roberts is a PLuS Alliance Professor appointed across 3 universities: UNSW, King's College London and Arizona State University. Dr. Roberts holds a BE (Honours) in Chemical Engineering (UNSW), an MBA (Macquarie University) and a PhD (UNSW) and was awarded Honorary Doctor of Sciences degrees from Macquarie University and the University of NSW. He is a member of the Board of Governors of the Centenary Institute of Cancer Medicine and Cell Biology, and is an Honorary Fellow of the Australian Institute of Business and Economics at the University of Queensland.

Additionally, he is a Fellow of the Academy of Technological Sciences and Engineering (FTSE), Fellow of the Australian Institute of Company Directors (FAICD) and Honorary Fellow of The Institution of Engineers Australia (FIEAust).

OncoSil Medical CEO Daniel Kenny said: *"We are grateful for the contribution of Dr. Roberts since he joined OncoSil as a Non-Executive Director, and are confident his expertise will continue to prove invaluable as he leads our Board. Dr. Roberts boasts a history of success in the development and commercialisation of medical technologies and his new appointment is very timely as we continue to advance toward commercialisation of a medical radiation treatment for pancreatic cancer and other solid tumors."*

In response to his appointment, Dr. Roberts said: *"I am excited to lead the Board as OncoSil draws nearer to commercialising its innovative technology which has the potential to significantly improve the lives of people with cancer. There have been several rewarding developments in recent months with the progression of the global pancreatic study programme, and I look forward to extending my involvement in the company's overall direction."*

- ENDS -

Company	Media
<p>Mr Daniel Kenny CEO & Managing Director E: daniel.kenny@oncosil.com.au T: +61 2 9223 3344</p>	<p>Ben Walsh WE Buchan E: bwalsh@buchanwe.com.au M: 0411 520 012</p>

About OncoSil

OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical’s lead product, OncoSil™ is a targeted radioactive isotope (Phosphorous-32), implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound.

Treatment with OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted four clinical studies with encouraging results on tolerability, safety and efficacy. A CE Mark application to commercially sell OncoSil™ in the European Union (EU) is under review with commercial launch, subject to approval.

An Investigational Device Exemption (IDE) has been granted by the United States Food and Drug Administration (FDA) to conduct a clinical study of the OncoSil™ device aimed at supporting a PMA approval. Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$1b.

Hepatocellular carcinoma (HCC) or liver cancer, is the 6th most common cancer in the world with 782,000 new cases diagnosed in 2012. While hepatocellular carcinoma can be treated by surgery or transplantation, the majority of patients with HCC have disease which is too advanced for surgery and their survival ranges from a few months to two or more years. The value of the hepatocellular cancer market is expected to triple in size to \$1.4b by 2019.